Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Phase 2

Completed

Conditions: Suspected or Documented Gram-negative Bacterial Infection

Interventions: Drug: IMI/REL
Drug: Active Control
Drug: Oral Switch

First Posted Date: 2019-05-31

Last Posted Date: 2025-05-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 115

Registration Number: NCT03969901

Locations: 🇿🇦
Molotlegi Street ( Site 0155), Pretoria, Gauteng, South Africa
🇪🇸
Hospital Infantil Universitario Nino Jesus ( Site 0114), Madrid, Spain
🇹🇷
Cukurova University Medical Faculty ( Site 0200), Adana, Turkey

and more 64 locations

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Phase 3

Completed

Conditions: Pneumonia, Pneumococcal
Pneumococcal Infections

Interventions: Drug: Prevnar 13™
Drug: V114

First Posted Date: 2019-05-15

Last Posted Date: 2021-04-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 2340

Registration Number: NCT03950856

Locations: 🇺🇸
L&C Professional Medical Research Institute ( Site 1012), Miami, Florida, United States
🇺🇸
Alpha Science Research ( Site 1015), Miami, Florida, United States
🇺🇸
Advanced Clinical Research ( Site 1028), West Jordan, Utah, United States

and more 52 locations

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: V114
Biological: Prevnar 13®

First Posted Date: 2019-05-15

Last Posted Date: 2021-04-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1205

Registration Number: NCT03950622

Locations: 🇨🇳
National Cheng Kung University Hospital ( Site 0501), Taiwan, Taiwan
🇺🇸
Charlottesville Medical Research Center, LLC ( Site 1003), Charlottesville, Virginia, United States
🇨🇦
Bluewater Clinical Research Group Inc ( Site 2004), Sarnia, Ontario, Canada

and more 27 locations

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Phase 3

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Biological: Pembrolizumab 200 mg
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Dietary Supplement: Folic acid 350-1000 μg
Drug: Dexamethasone 4 mg
Dietary Supplement: Vitamin B12 1000 μg
Drug: Saline solution

First Posted Date: 2019-05-15

Last Posted Date: 2024-06-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 40

Registration Number: NCT03950674

Locations: 🇯🇵
National Hospital Organization Nagoya Medical Center ( Site 0324), Nagoya, Aichi, Japan
🇯🇵
The Cancer Institute Hospital of JFCR ( Site 0323), Tokyo, Japan
🇯🇵
Kurume University Hospital ( Site 0326), Kurume, Fukuoka, Japan

and more 7 locations

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Phase 1

Terminated

Conditions: Neoplasms
Carcinoma, Non-Small-Cell Lung
Pancreatic Neoplasms
Colorectal Neoplasms

Interventions: Biological: V941
Biological: Pembrolizumab

First Posted Date: 2019-05-14

Last Posted Date: 2025-01-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 70

Registration Number: NCT03948763

Locations: 🇺🇸
University of California at San Francisco ( Site 1006), San Francisco, California, United States
🇺🇸
Smilow Cancer Hospital at Yale New Haven ( Site 1005), New Haven, Connecticut, United States
🇺🇸
Tennessee Oncology Nashville Drug Development Unit ( Site 7000), Nashville, Tennessee, United States

and more 23 locations

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

Phase 2

Completed

Conditions: Cytomegalovirus (CMV) Infection

Interventions: Drug: Letermovir oral granules
Drug: Letermovir tablet
Drug: Letermovir intravenous

First Posted Date: 2019-05-07

Last Posted Date: 2024-08-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 65

Registration Number: NCT03940586

Locations: 🇺🇸
Seattle Childrens Hospital ( Site 0248), Seattle, Washington, United States
🇺🇸
UCSF Benioff Children's Hospital San Francisco ( Site 0245), San Francisco, California, United States
🇮🇱
Pediatric Hemato Oncology Safra Children's Hospital, Sheba Medical Center ( Site 0123), Ramat Gan, Israel

and more 37 locations

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Phase 3

Completed

Conditions: Esophageal Carcinoma
Esophagogastric Junction Carcinoma

Interventions: Biological: pembrolizumab
Drug: paclitaxel
Drug: docetaxel
Drug: irinotecan

First Posted Date: 2019-05-01

Last Posted Date: 2023-03-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 123

Registration Number: NCT03933449

Locations: 🇨🇳
Wuhan Tongji Hospital ( Site 0724), Wuhan, Hubei, China
🇨🇳
Jiangsu Cancer Hospital (Site 0704), Nanjing, Jiangsu, China
🇨🇳
The First Affiliated Hospital of Anhui Medical University ( Site 0707), Hefei, Anhui, China

and more 20 locations

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

Phase 3

Completed

Conditions: Cytomegalovirus Infection

Interventions: Drug: Letermovir
Drug: Placebo

First Posted Date: 2019-04-29

Last Posted Date: 2024-08-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 220

Registration Number: NCT03930615

Locations: 🇺🇸
Indiana Blood and Marrow Transplantation ( Site 0175), Indianapolis, Indiana, United States
🇺🇸
The University of Texas MD Anderson Cancer Center ( Site 0154), Houston, Texas, United States
🇫🇷
Centre Hospitalier Universitaire Dupuytren ( Site 0182), Limoges, Haute-Vienne, France

and more 29 locations

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Phase 3

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Cisplatin
Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Drug: Placebo

First Posted Date: 2019-04-23

Last Posted Date: 2025-03-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 907

Registration Number: NCT03924856

Locations: 🇨🇦
Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada
🇺🇸
Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033), Seattle, Washington, United States
🇺🇸
Scripps MD Anderson ( Site 0010), La Jolla, California, United States

and more 172 locations

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT)
Biological: Pembrolizumab
Drug: Placebo

First Posted Date: 2019-04-23

Last Posted Date: 2025-05-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 448

Registration Number: NCT03924869

Locations: 🇨🇦
Trillium Health Partners - Credit Valley Hospital ( Site 0102), Mississauga, Ontario, Canada
🇨🇦
Moncton Hospital - Horizon Health Network ( Site 0105), Moncton, New Brunswick, Canada
🇨🇦
Kingston Health Sciences Centre ( Site 0100), Kingston, Ontario, Canada

and more 191 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy